Nibbler SEO audit for openmedscience.com

Overall8.7

The overall score for this website.

Accessibility9.8

How accessible the website is to mobile and disabled users.

The following tests contribute to this score:

Experience9.5

How satisfying the website is likely to be for users.

The following tests contribute to this score:

Marketing8.4

How well marketed and popular the website is.

The following tests contribute to this score:

Technology9.1

How well designed and built the website is.

The following tests contribute to this score:

Nibbler tested a sample of 5 pages from this website at 11:44 PM on May 10, 2024 (BST).

Want white-label SEO audits to share with your clients?

Top priorities for website improvement

  • Consider a leading website analytics solution, such as WebTrends or Google Analytics. (read more)
  • The width and height you specify in an image tag should be the same as the source image. If you want to resize an image in the browser, use the CSS width and height properties. (read more)
  • Ensure your web server returns a 404 HTTP status code for error pages. (read more)

Analytics0.0

Help

0% of pages use analytics

No Analytics SolutionNo

  • None of this website is using any recognised analytics software. It is still possible to gather a great deal of information from webserver logs, however complete visitor analysis requires client-side Javascript or an image not found here.
    • Consider a leading website analytics solution, such as WebTrends or Google Analytics.
  • Note that this test can only detect recognised analytics solutions. If an analytics solution is new, obscure or used in a non-standard way (e.g. it has been customised) it may not be detected.

Server behavior8.0

Help

No404 page

YesCompression

  • This website does not return a 404 error HTTP status code for missing pages. This is bad because search engines like Google might mistake this for a real page of content.
  • This website was served with GZIP encoding. This is very good because it reduces the loading time of a web page.
  • This website follows the best practice of using a permanent (HTTP 301) redirect between URLs with/without trailing slashes. This is ideal.
  • This website follows the best practice of using a permanent (HTTP 301) redirect from http://www.openmedscience.com to http://openmedscience.com. This is ideal.

Images8.0

Help

100% of images have a clearly defined size

12 images are being resized by the browser

Internal links9.2

Help

Headings9.8

Help

abstract actinium- activity advances agents ai-driven article articles blog blogger cancer celebrating challenges changing clinical conclusion conflict contrast cookies counseling current diagnostics digital dosimetry dota-ys emerging future health hertz honoring imaging information innovations interest introduction isotopes issues links magnetic marker medical medscience mental methods microsphere microspheres navigating neuroendocrine open other perspective posting precision prostate radiology radiotheranostics radiotherapy recent references resonance revolution saul techniques theranostics therapy topics treatment tumors websites world

  • All pages were found to use defined headings. This is excellent as it allows visitors and search engines to summarize the content of webpages quickly. Correctly defined headings aid accessibility and are particularly important for search engine optimization.
  • Some headings (3.0%) were found to be empty, or incorrectly defined. Empty or invalid headings are of no value to search engines and make a website less accessible.
    • Make sure all headings have content which is relevant to the page of content.

Page headings detail

URLHeadingLevel
openmedscience.com/Open MedScienceH1
openmedscience.com/Open MedScienceH1
openmedscience.com/Medical Imaging TechnologiesH1
openmedscience.com/Hot TopicsH2
openmedscience.com/Revolutionising RadiotherapyH2
openmedscience.com/Precision Radiotheranostics in CancerH2
openmedscience.com/Radiation Therapy Devices in Cancer TreatmentH2
openmedscience.com/Artificial Intelligence in the Field of RadiologyH2
openmedscience.com/Recent Blog ArticlesH2
openmedscience.com/AboutH2
openmedscience.com/PostingH2
openmedscience.com/BloggerH2
openmedscience.com/How we use cookiesH2
openmedscience.com/Links to other websitesH2
openmedscience.com/Donate and Receive a Free Medical Imaging BookH3
openmedscience.com/The Digital Revolution: How AI Is Changing Mental Health CounselingH4
openmedscience.com/Celebrating World Theranostics Day Honoring Saul HertzH4
openmedscience.com/AI in Radiology Navigating the Future with AI-Driven DiagnosticsH4
openmedscience.com/Magnetic Resonance Imaging (MRI): Innovations and Advances in Contrast AgentsH4
openmedscience.com/18f-fluoride-as-a-marker-of-unstable-atheroma-a-perspective/18F-Fluoride as a marker of unstable atheroma – a perspectiveH1
openmedscience.com/18f-fluoride-as-a-marker-of-unstable-atheroma-a-perspective/Hot TopicsH2
openmedscience.com/18f-fluoride-as-a-marker-of-unstable-atheroma-a-perspective/AbstractH2
openmedscience.com/18f-fluoride-as-a-marker-of-unstable-atheroma-a-perspective/PerspectiveH2
openmedscience.com/18f-fluoride-as-a-marker-of-unstable-atheroma-a-perspective/Conflict of interestH2
openmedscience.com/18f-fluoride-as-a-marker-of-unstable-atheroma-a-perspective/ReferencesH2
openmedscience.com/18f-fluoride-as-a-marker-of-unstable-atheroma-a-perspective/Suggested readingH2
openmedscience.com/18f-fluoride-as-a-marker-of-unstable-atheroma-a-perspective/Article informationH2
openmedscience.com/18f-fluoride-as-a-marker-of-unstable-atheroma-a-perspective/Recent Blog ArticlesH2
openmedscience.com/18f-fluoride-as-a-marker-of-unstable-atheroma-a-perspective/AboutH2
openmedscience.com/18f-fluoride-as-a-marker-of-unstable-atheroma-a-perspective/PostingH2
openmedscience.com/18f-fluoride-as-a-marker-of-unstable-atheroma-a-perspective/BloggerH2
openmedscience.com/18f-fluoride-as-a-marker-of-unstable-atheroma-a-perspective/How we use cookiesH2
openmedscience.com/18f-fluoride-as-a-marker-of-unstable-atheroma-a-perspective/Links to other websitesH2
openmedscience.com/18f-fluoride-as-a-marker-of-unstable-atheroma-a-perspective/The Digital Revolution: How AI Is Changing Mental Health CounselingH4
openmedscience.com/18f-fluoride-as-a-marker-of-unstable-atheroma-a-perspective/Celebrating World Theranostics Day Honoring Saul HertzH4
openmedscience.com/18f-fluoride-as-a-marker-of-unstable-atheroma-a-perspective/AI in Radiology Navigating the Future with AI-Driven DiagnosticsH4
openmedscience.com/18f-fluoride-as-a-marker-of-unstable-atheroma-a-perspective/Magnetic Resonance Imaging (MRI): Innovations and Advances in Contrast AgentsH4
openmedscience.com/a-review-of-3d-image-based-dosimetry-technical-considerations-and-emerging-perspectives-in-90y-microsphere-therapy/A review of 3D image-based dosimetry, technical considerations and emerging perspectives in 90Y microsphere therapyH1
openmedscience.com/a-review-of-3d-image-based-dosimetry-technical-considerations-and-emerging-perspectives-in-90y-microsphere-therapy/Hot TopicsH2
openmedscience.com/a-review-of-3d-image-based-dosimetry-technical-considerations-and-emerging-perspectives-in-90y-microsphere-therapy/AbstractH2
openmedscience.com/a-review-of-3d-image-based-dosimetry-technical-considerations-and-emerging-perspectives-in-90y-microsphere-therapy/1. IntroductionH2
openmedscience.com/a-review-of-3d-image-based-dosimetry-technical-considerations-and-emerging-perspectives-in-90y-microsphere-therapy/2. Current techniquesH2
openmedscience.com/a-review-of-3d-image-based-dosimetry-technical-considerations-and-emerging-perspectives-in-90y-microsphere-therapy/3. Current issues in 90Y therapyH2
openmedscience.com/a-review-of-3d-image-based-dosimetry-technical-considerations-and-emerging-perspectives-in-90y-microsphere-therapy/4. Dosimetry methods in 90Y-REH2
openmedscience.com/a-review-of-3d-image-based-dosimetry-technical-considerations-and-emerging-perspectives-in-90y-microsphere-therapy/5. Emerging directionsH2
openmedscience.com/a-review-of-3d-image-based-dosimetry-technical-considerations-and-emerging-perspectives-in-90y-microsphere-therapy/6. ConclusionsH2
openmedscience.com/a-review-of-3d-image-based-dosimetry-technical-considerations-and-emerging-perspectives-in-90y-microsphere-therapy/Conflict of interestH2
openmedscience.com/a-review-of-3d-image-based-dosimetry-technical-considerations-and-emerging-perspectives-in-90y-microsphere-therapy/AcknowledgementsH2
openmedscience.com/a-review-of-3d-image-based-dosimetry-technical-considerations-and-emerging-perspectives-in-90y-microsphere-therapy/ReferencesH2
openmedscience.com/a-review-of-3d-image-based-dosimetry-technical-considerations-and-emerging-perspectives-in-90y-microsphere-therapy/Article informationH2
openmedscience.com/a-review-of-3d-image-based-dosimetry-technical-considerations-and-emerging-perspectives-in-90y-microsphere-therapy/Recent Blog ArticlesH2
openmedscience.com/a-review-of-3d-image-based-dosimetry-technical-considerations-and-emerging-perspectives-in-90y-microsphere-therapy/AboutH2
openmedscience.com/a-review-of-3d-image-based-dosimetry-technical-considerations-and-emerging-perspectives-in-90y-microsphere-therapy/PostingH2
openmedscience.com/a-review-of-3d-image-based-dosimetry-technical-considerations-and-emerging-perspectives-in-90y-microsphere-therapy/BloggerH2
openmedscience.com/a-review-of-3d-image-based-dosimetry-technical-considerations-and-emerging-perspectives-in-90y-microsphere-therapy/How we use cookiesH2
openmedscience.com/a-review-of-3d-image-based-dosimetry-technical-considerations-and-emerging-perspectives-in-90y-microsphere-therapy/Links to other websitesH2
openmedscience.com/a-review-of-3d-image-based-dosimetry-technical-considerations-and-emerging-perspectives-in-90y-microsphere-therapy/2.1 ProcedureH3
openmedscience.com/a-review-of-3d-image-based-dosimetry-technical-considerations-and-emerging-perspectives-in-90y-microsphere-therapy/2.2 Activity Planning  H3
openmedscience.com/a-review-of-3d-image-based-dosimetry-technical-considerations-and-emerging-perspectives-in-90y-microsphere-therapy/2.3 Differences between RMS and GMSH3
openmedscience.com/a-review-of-3d-image-based-dosimetry-technical-considerations-and-emerging-perspectives-in-90y-microsphere-therapy/3.1 Assaying the ActivityH3
openmedscience.com/a-review-of-3d-image-based-dosimetry-technical-considerations-and-emerging-perspectives-in-90y-microsphere-therapy/3.2 Limitations of current dosimetry modelsH3
openmedscience.com/a-review-of-3d-image-based-dosimetry-technical-considerations-and-emerging-perspectives-in-90y-microsphere-therapy/3.3 Determination of lung shunt fraction (LSF)  H3
openmedscience.com/a-review-of-3d-image-based-dosimetry-technical-considerations-and-emerging-perspectives-in-90y-microsphere-therapy/3.4 Quantitative 90Y reconstructionH3
openmedscience.com/a-review-of-3d-image-based-dosimetry-technical-considerations-and-emerging-perspectives-in-90y-microsphere-therapy/3.5 Using 99mTc-MAA as a 90Y MS surrogateH3
openmedscience.com/a-review-of-3d-image-based-dosimetry-technical-considerations-and-emerging-perspectives-in-90y-microsphere-therapy/3.6 Microsphere distributionH3
openmedscience.com/a-review-of-3d-image-based-dosimetry-technical-considerations-and-emerging-perspectives-in-90y-microsphere-therapy/4.1 Direct Monte CarloH3
openmedscience.com/a-review-of-3d-image-based-dosimetry-technical-considerations-and-emerging-perspectives-in-90y-microsphere-therapy/4.1.1 MC User-end codesH3
openmedscience.com/a-review-of-3d-image-based-dosimetry-technical-considerations-and-emerging-perspectives-in-90y-microsphere-therapy/4.2 Dose kernel convolution methods  H3
openmedscience.com/a-review-of-3d-image-based-dosimetry-technical-considerations-and-emerging-perspectives-in-90y-microsphere-therapy/4.3 Local Deposition Method (LDM)H3
openmedscience.com/a-review-of-3d-image-based-dosimetry-technical-considerations-and-emerging-perspectives-in-90y-microsphere-therapy/4.4 Dose-Response RelationshipH3
openmedscience.com/a-review-of-3d-image-based-dosimetry-technical-considerations-and-emerging-perspectives-in-90y-microsphere-therapy/5.1 90Y PET Imaging  H3
openmedscience.com/a-review-of-3d-image-based-dosimetry-technical-considerations-and-emerging-perspectives-in-90y-microsphere-therapy/5.2 Preplanning with PET isotopes  H3
openmedscience.com/a-review-of-3d-image-based-dosimetry-technical-considerations-and-emerging-perspectives-in-90y-microsphere-therapy/5.3 Other Treatment Isotopes  H3
openmedscience.com/a-review-of-3d-image-based-dosimetry-technical-considerations-and-emerging-perspectives-in-90y-microsphere-therapy/5.4 Delivery of SpheresH3
openmedscience.com/a-review-of-3d-image-based-dosimetry-technical-considerations-and-emerging-perspectives-in-90y-microsphere-therapy/5.5 “Extended shelf-life” TechniqueH3
openmedscience.com/a-review-of-3d-image-based-dosimetry-technical-considerations-and-emerging-perspectives-in-90y-microsphere-therapy/2.2.1 Resin Microspheres (RMS)H4
openmedscience.com/a-review-of-3d-image-based-dosimetry-technical-considerations-and-emerging-perspectives-in-90y-microsphere-therapy/2.2.2 Glass Microspheres (GMS)H4
openmedscience.com/a-review-of-3d-image-based-dosimetry-technical-considerations-and-emerging-perspectives-in-90y-microsphere-therapy/The Digital Revolution: How AI Is Changing Mental Health CounselingH4
openmedscience.com/a-review-of-3d-image-based-dosimetry-technical-considerations-and-emerging-perspectives-in-90y-microsphere-therapy/Celebrating World Theranostics Day Honoring Saul HertzH4
openmedscience.com/a-review-of-3d-image-based-dosimetry-technical-considerations-and-emerging-perspectives-in-90y-microsphere-therapy/AI in Radiology Navigating the Future with AI-Driven DiagnosticsH4
openmedscience.com/a-review-of-3d-image-based-dosimetry-technical-considerations-and-emerging-perspectives-in-90y-microsphere-therapy/Magnetic Resonance Imaging (MRI): Innovations and Advances in Contrast AgentsH4
openmedscience.com/68ga-somatostatin-analogue-pet-ct-in-neuroendocrine-tumors/68Ga-Somatostatin analogue PET/CT in neuroendocrine tumorsH1
openmedscience.com/68ga-somatostatin-analogue-pet-ct-in-neuroendocrine-tumors/Hot TopicsH2
openmedscience.com/68ga-somatostatin-analogue-pet-ct-in-neuroendocrine-tumors/AbstractH2
openmedscience.com/68ga-somatostatin-analogue-pet-ct-in-neuroendocrine-tumors/IntroductionH2
openmedscience.com/68ga-somatostatin-analogue-pet-ct-in-neuroendocrine-tumors/Imaging modalitiesH2
openmedscience.com/68ga-somatostatin-analogue-pet-ct-in-neuroendocrine-tumors/Clinical indication to perform 68Ga-DOTA-conjugate peptides PET/CTH2
openmedscience.com/68ga-somatostatin-analogue-pet-ct-in-neuroendocrine-tumors/ConclusionH2
openmedscience.com/68ga-somatostatin-analogue-pet-ct-in-neuroendocrine-tumors/Conflict of interestH2
openmedscience.com/68ga-somatostatin-analogue-pet-ct-in-neuroendocrine-tumors/ReferencesH2
openmedscience.com/68ga-somatostatin-analogue-pet-ct-in-neuroendocrine-tumors/Article informationH2
openmedscience.com/68ga-somatostatin-analogue-pet-ct-in-neuroendocrine-tumors/Recent Blog ArticlesH2
openmedscience.com/68ga-somatostatin-analogue-pet-ct-in-neuroendocrine-tumors/AboutH2
openmedscience.com/68ga-somatostatin-analogue-pet-ct-in-neuroendocrine-tumors/PostingH2
openmedscience.com/68ga-somatostatin-analogue-pet-ct-in-neuroendocrine-tumors/BloggerH2
openmedscience.com/68ga-somatostatin-analogue-pet-ct-in-neuroendocrine-tumors/How we use cookiesH2
openmedscience.com/68ga-somatostatin-analogue-pet-ct-in-neuroendocrine-tumors/Links to other websitesH2
openmedscience.com/68ga-somatostatin-analogue-pet-ct-in-neuroendocrine-tumors/BiologyH3
openmedscience.com/68ga-somatostatin-analogue-pet-ct-in-neuroendocrine-tumors/Classification of neuroendocrine tumorsH3
openmedscience.com/68ga-somatostatin-analogue-pet-ct-in-neuroendocrine-tumors/Computed tomographyH3
openmedscience.com/68ga-somatostatin-analogue-pet-ct-in-neuroendocrine-tumors/Magnetic resonance imagingH3
openmedscience.com/68ga-somatostatin-analogue-pet-ct-in-neuroendocrine-tumors/Somatostatin receptor imagingH3
openmedscience.com/68ga-somatostatin-analogue-pet-ct-in-neuroendocrine-tumors/ScintigraphyH3
openmedscience.com/68ga-somatostatin-analogue-pet-ct-in-neuroendocrine-tumors/PET/CT-68Ga-DOTA-SSTRTsH3
openmedscience.com/68ga-somatostatin-analogue-pet-ct-in-neuroendocrine-tumors/PET/CT-18F-FDGH3
openmedscience.com/68ga-somatostatin-analogue-pet-ct-in-neuroendocrine-tumors/StagingH3
openmedscience.com/68ga-somatostatin-analogue-pet-ct-in-neuroendocrine-tumors/TherapyH3
openmedscience.com/68ga-somatostatin-analogue-pet-ct-in-neuroendocrine-tumors/Treatment responseH3
openmedscience.com/68ga-somatostatin-analogue-pet-ct-in-neuroendocrine-tumors/RecurrenceH3
openmedscience.com/68ga-somatostatin-analogue-pet-ct-in-neuroendocrine-tumors/Pediatric NETH3
openmedscience.com/68ga-somatostatin-analogue-pet-ct-in-neuroendocrine-tumors/The Digital Revolution: How AI Is Changing Mental Health CounselingH4
openmedscience.com/68ga-somatostatin-analogue-pet-ct-in-neuroendocrine-tumors/Celebrating World Theranostics Day Honoring Saul HertzH4
openmedscience.com/68ga-somatostatin-analogue-pet-ct-in-neuroendocrine-tumors/AI in Radiology Navigating the Future with AI-Driven DiagnosticsH4
openmedscience.com/68ga-somatostatin-analogue-pet-ct-in-neuroendocrine-tumors/Magnetic Resonance Imaging (MRI): Innovations and Advances in Contrast AgentsH4
openmedscience.com/actinium-225-dota-ys5-a-novel-cd46-targeted-radiopharmaceutical-for-prostate-cancer-therapy/Actinium-225 DOTA-YS5: A Novel CD46-Targeted Radiopharmaceutical for Prostate Cancer TherapyH1
openmedscience.com/actinium-225-dota-ys5-a-novel-cd46-targeted-radiopharmaceutical-for-prostate-cancer-therapy/Hot TopicsH2
openmedscience.com/actinium-225-dota-ys5-a-novel-cd46-targeted-radiopharmaceutical-for-prostate-cancer-therapy/Background on Prostate Cancer and Therapeutic ChallengesH2
openmedscience.com/actinium-225-dota-ys5-a-novel-cd46-targeted-radiopharmaceutical-for-prostate-cancer-therapy/Introduction of Actinium-225 DOTA-YS5H2
openmedscience.com/actinium-225-dota-ys5-a-novel-cd46-targeted-radiopharmaceutical-for-prostate-cancer-therapy/Future Prospects and ChallengesH2
openmedscience.com/actinium-225-dota-ys5-a-novel-cd46-targeted-radiopharmaceutical-for-prostate-cancer-therapy/ConclusionH2
openmedscience.com/actinium-225-dota-ys5-a-novel-cd46-targeted-radiopharmaceutical-for-prostate-cancer-therapy/Recent Blog ArticlesH2
openmedscience.com/actinium-225-dota-ys5-a-novel-cd46-targeted-radiopharmaceutical-for-prostate-cancer-therapy/AboutH2
openmedscience.com/actinium-225-dota-ys5-a-novel-cd46-targeted-radiopharmaceutical-for-prostate-cancer-therapy/PostingH2
openmedscience.com/actinium-225-dota-ys5-a-novel-cd46-targeted-radiopharmaceutical-for-prostate-cancer-therapy/BloggerH2
openmedscience.com/actinium-225-dota-ys5-a-novel-cd46-targeted-radiopharmaceutical-for-prostate-cancer-therapy/How we use cookiesH2
openmedscience.com/actinium-225-dota-ys5-a-novel-cd46-targeted-radiopharmaceutical-for-prostate-cancer-therapy/Links to other websitesH2
openmedscience.com/actinium-225-dota-ys5-a-novel-cd46-targeted-radiopharmaceutical-for-prostate-cancer-therapy/The Role of CD46 in Prostate CancerH3
openmedscience.com/actinium-225-dota-ys5-a-novel-cd46-targeted-radiopharmaceutical-for-prostate-cancer-therapy/Mechanism of ActionH3
openmedscience.com/actinium-225-dota-ys5-a-novel-cd46-targeted-radiopharmaceutical-for-prostate-cancer-therapy/Advantages over Traditional TherapiesH3
openmedscience.com/actinium-225-dota-ys5-a-novel-cd46-targeted-radiopharmaceutical-for-prostate-cancer-therapy/Companion Diagnostic – 89Zr-DFO-YS5H3
openmedscience.com/actinium-225-dota-ys5-a-novel-cd46-targeted-radiopharmaceutical-for-prostate-cancer-therapy/Clinical Trials and Research ProgressH3
openmedscience.com/actinium-225-dota-ys5-a-novel-cd46-targeted-radiopharmaceutical-for-prostate-cancer-therapy/Patient Selection and Personalised MedicineH3
openmedscience.com/actinium-225-dota-ys5-a-novel-cd46-targeted-radiopharmaceutical-for-prostate-cancer-therapy/Understanding Side Effects and Long-term ImpactsH3
openmedscience.com/actinium-225-dota-ys5-a-novel-cd46-targeted-radiopharmaceutical-for-prostate-cancer-therapy/Overcoming Resistance and HeterogeneityH3
openmedscience.com/actinium-225-dota-ys5-a-novel-cd46-targeted-radiopharmaceutical-for-prostate-cancer-therapy/Integration into Current Treatment ParadigmsH3
openmedscience.com/actinium-225-dota-ys5-a-novel-cd46-targeted-radiopharmaceutical-for-prostate-cancer-therapy/Regulatory Hurdles and AccessibilityH3
openmedscience.com/actinium-225-dota-ys5-a-novel-cd46-targeted-radiopharmaceutical-for-prostate-cancer-therapy/Potential for Other CancersH3
openmedscience.com/actinium-225-dota-ys5-a-novel-cd46-targeted-radiopharmaceutical-for-prostate-cancer-therapy/The Digital Revolution: How AI Is Changing Mental Health CounselingH4
openmedscience.com/actinium-225-dota-ys5-a-novel-cd46-targeted-radiopharmaceutical-for-prostate-cancer-therapy/Celebrating World Theranostics Day Honoring Saul HertzH4
openmedscience.com/actinium-225-dota-ys5-a-novel-cd46-targeted-radiopharmaceutical-for-prostate-cancer-therapy/AI in Radiology Navigating the Future with AI-Driven DiagnosticsH4
openmedscience.com/actinium-225-dota-ys5-a-novel-cd46-targeted-radiopharmaceutical-for-prostate-cancer-therapy/Magnetic Resonance Imaging (MRI): Innovations and Advances in Contrast AgentsH4

Mobile10.0

Help

Mobile screenshot of openmedscience.comTablet screenshot of openmedscience.com
  • All of this website appears to be optimised for viewing on a mobile phone or a tablet.

Media specific CSS detected

Page titles10.0

Help

100% of pages have defined titles

0% of page titles are weak

  • All pages were found to use page titles appropriately. Page titles appear in search results and at the top of the browser's window when visiting the site. Appropriate page titles are particularly important for search engine optimization.

Page titles

Meta tags10.0

Help

This is how this website will look in Google search listings:

Medical Imaging Technologies | Open Medscience

openmedscience.com/

Diagnostic medical imaging technologies, such as radiology, radiation therapy, X-rays, CT, and MRI, allow diagnostics and radiotheranostics.

  • All pages were found to include a meta description. This is good because search engines (like Google) show this text in search result pages.

Meta Tags (name attribute)

Page URLNameContent
openmedscience.com/viewportwidth=device-width, initial-scale=1
openmedscience.com/robotsindex, follow, max-image-preview:large, max-snippet:-1, max-video-preview:-1
openmedscience.com/descriptionDiagnostic medical imaging technologies, such as radiology, radiation therapy, X-rays, CT, and MRI, allow diagnostics and radiotheranostics.
openmedscience.com/twitter:cardsummary_large_image
openmedscience.com/twitter:site@OpenMedscience
openmedscience.com/google-site-verificationNxXnntBM2BOo1hQMgjjnwEg9FZgStki2z8pLw1FKRrE
openmedscience.com/p:domain_verifyea9335bbcedd85d03a7b8750281587d1
openmedscience.com/yandex-verification274e54e3b82eec4b
openmedscience.com/generatorWordPress 6.5.3
openmedscience.com/msapplication-tileimagehttps://openmedscience.com/wp-content/uploads/2019/04/Open-Medscience-Logo-e1590311804280.jpg
openmedscience.com/18f-fluoride-as-a-marker-of-unstable-atheroma-a-perspective/viewportwidth=device-width, initial-scale=1
openmedscience.com/18f-fluoride-as-a-marker-of-unstable-atheroma-a-perspective/robotsindex, follow, max-image-preview:large, max-snippet:-1, max-video-preview:-1
openmedscience.com/18f-fluoride-as-a-marker-of-unstable-atheroma-a-perspective/descriptionCharacterization of unstable atheroma allow a therapeutic intervention by using PET-CT imaging of atherosclerosis and microcalcification.
openmedscience.com/18f-fluoride-as-a-marker-of-unstable-atheroma-a-perspective/twitter:cardsummary_large_image
openmedscience.com/18f-fluoride-as-a-marker-of-unstable-atheroma-a-perspective/twitter:site@OpenMedscience
openmedscience.com/18f-fluoride-as-a-marker-of-unstable-atheroma-a-perspective/twitter:label1Estimated reading time
openmedscience.com/18f-fluoride-as-a-marker-of-unstable-atheroma-a-perspective/twitter:data115 minutes
openmedscience.com/18f-fluoride-as-a-marker-of-unstable-atheroma-a-perspective/generatorWordPress 6.5.3
openmedscience.com/18f-fluoride-as-a-marker-of-unstable-atheroma-a-perspective/msapplication-tileimagehttps://openmedscience.com/wp-content/uploads/2019/04/Open-Medscience-Logo-e1590311804280.jpg
openmedscience.com/a-review-of-3d-image-based-dosimetry-technical-considerations-and-emerging-perspectives-in-90y-microsphere-therapy/viewportwidth=device-width, initial-scale=1
openmedscience.com/a-review-of-3d-image-based-dosimetry-technical-considerations-and-emerging-perspectives-in-90y-microsphere-therapy/robotsindex, follow, max-image-preview:large, max-snippet:-1, max-video-preview:-1
openmedscience.com/a-review-of-3d-image-based-dosimetry-technical-considerations-and-emerging-perspectives-in-90y-microsphere-therapy/descriptionDosimetry 90Y microsphere therapy in the treatment of hepatocellular carcinoma. 90Y-RE quantification and dosimetry are reviewed.
openmedscience.com/a-review-of-3d-image-based-dosimetry-technical-considerations-and-emerging-perspectives-in-90y-microsphere-therapy/twitter:cardsummary_large_image
openmedscience.com/a-review-of-3d-image-based-dosimetry-technical-considerations-and-emerging-perspectives-in-90y-microsphere-therapy/twitter:site@OpenMedscience
openmedscience.com/a-review-of-3d-image-based-dosimetry-technical-considerations-and-emerging-perspectives-in-90y-microsphere-therapy/generatorWordPress 6.5.3
openmedscience.com/a-review-of-3d-image-based-dosimetry-technical-considerations-and-emerging-perspectives-in-90y-microsphere-therapy/msapplication-tileimagehttps://openmedscience.com/wp-content/uploads/2019/04/Open-Medscience-Logo-e1590311804280.jpg
openmedscience.com/68ga-somatostatin-analogue-pet-ct-in-neuroendocrine-tumors/viewportwidth=device-width, initial-scale=1
openmedscience.com/68ga-somatostatin-analogue-pet-ct-in-neuroendocrine-tumors/robotsindex, follow, max-image-preview:large, max-snippet:-1, max-video-preview:-1
openmedscience.com/68ga-somatostatin-analogue-pet-ct-in-neuroendocrine-tumors/descriptionNeuroendocrine tumours were imaged with 68Ga-Dota-SST radiotracers and somatostatin receptor scintigraphy PET/CT scanning 68Ga-Somatostatin.
openmedscience.com/68ga-somatostatin-analogue-pet-ct-in-neuroendocrine-tumors/twitter:cardsummary_large_image
openmedscience.com/68ga-somatostatin-analogue-pet-ct-in-neuroendocrine-tumors/twitter:site@OpenMedscience
openmedscience.com/68ga-somatostatin-analogue-pet-ct-in-neuroendocrine-tumors/twitter:label1Estimated reading time
openmedscience.com/68ga-somatostatin-analogue-pet-ct-in-neuroendocrine-tumors/twitter:data139 minutes
openmedscience.com/68ga-somatostatin-analogue-pet-ct-in-neuroendocrine-tumors/generatorWordPress 6.5.3
openmedscience.com/68ga-somatostatin-analogue-pet-ct-in-neuroendocrine-tumors/msapplication-tileimagehttps://openmedscience.com/wp-content/uploads/2019/04/Open-Medscience-Logo-e1590311804280.jpg
openmedscience.com/actinium-225-dota-ys5-a-novel-cd46-targeted-radiopharmaceutical-for-prostate-cancer-therapy/viewportwidth=device-width, initial-scale=1
openmedscience.com/actinium-225-dota-ys5-a-novel-cd46-targeted-radiopharmaceutical-for-prostate-cancer-therapy/robotsindex, follow, max-image-preview:large, max-snippet:-1, max-video-preview:-1
openmedscience.com/actinium-225-dota-ys5-a-novel-cd46-targeted-radiopharmaceutical-for-prostate-cancer-therapy/descriptionActinium-225 DOTA-YS5 targets CD46 in advanced prostate cancer, promising precise treatment with reduced side effects.
openmedscience.com/actinium-225-dota-ys5-a-novel-cd46-targeted-radiopharmaceutical-for-prostate-cancer-therapy/twitter:cardsummary_large_image
openmedscience.com/actinium-225-dota-ys5-a-novel-cd46-targeted-radiopharmaceutical-for-prostate-cancer-therapy/twitter:site@OpenMedscience
openmedscience.com/actinium-225-dota-ys5-a-novel-cd46-targeted-radiopharmaceutical-for-prostate-cancer-therapy/twitter:label1Estimated reading time
openmedscience.com/actinium-225-dota-ys5-a-novel-cd46-targeted-radiopharmaceutical-for-prostate-cancer-therapy/twitter:data15 minutes
openmedscience.com/actinium-225-dota-ys5-a-novel-cd46-targeted-radiopharmaceutical-for-prostate-cancer-therapy/generatorWordPress 6.5.3
openmedscience.com/actinium-225-dota-ys5-a-novel-cd46-targeted-radiopharmaceutical-for-prostate-cancer-therapy/msapplication-tileimagehttps://openmedscience.com/wp-content/uploads/2019/04/Open-Medscience-Logo-e1590311804280.jpg

Printability10.0

Help

100% of pages are optimized for printing

  • All pages of this website appear to be optimized for printing (using CSS).

Media specific CSS detected

URL format10.0

Help

  • This website uses appropriate web addresses (URLs) throughout. This is excellent and will help search engine placement, usability and the marketability of this website.

Amount of content10.0

Help

Rendering Chart...

  • This website has an average of 6,680 words per page. The amount of content on a website has been shown to correlate with its search engine ranking.

Amount of content discovered

Freshness10.0

Help

Last updated April 23, 2024

  • It looks like this website was last updated on Tuesday, April 23, 2024. This is good because visitors perceive up-to-date websites as more credible. Websites that are updated regularly are also spidered by search engines more often.
  • To find this information we used the last modified dates reported by this website's server in addition to looking for dates written on each page.

All dates found

DateFileSource
7/19/22openmedscience.com/Body text
9/3/14openmedscience.com/18f-fluoride-as-a-marker-of-unstable-atheroma-a-perspective/Body text
11/6/14openmedscience.com/18f-fluoride-as-a-marker-of-unstable-atheroma-a-perspective/Body text
11/14/14openmedscience.com/18f-fluoride-as-a-marker-of-unstable-atheroma-a-perspective/Body text
11/17/14openmedscience.com/18f-fluoride-as-a-marker-of-unstable-atheroma-a-perspective/Body text
11/18/14openmedscience.com/18f-fluoride-as-a-marker-of-unstable-atheroma-a-perspective/Body text
7/19/22openmedscience.com/18f-fluoride-as-a-marker-of-unstable-atheroma-a-perspective/Body text
4/8/15openmedscience.com/a-review-of-3d-image-based-dosimetry-technical-considerations-and-emerging-perspectives-in-90y-microsphere-therapy/Body text
4/27/15openmedscience.com/a-review-of-3d-image-based-dosimetry-technical-considerations-and-emerging-perspectives-in-90y-microsphere-therapy/Body text
4/28/15openmedscience.com/a-review-of-3d-image-based-dosimetry-technical-considerations-and-emerging-perspectives-in-90y-microsphere-therapy/Body text
7/19/22openmedscience.com/a-review-of-3d-image-based-dosimetry-technical-considerations-and-emerging-perspectives-in-90y-microsphere-therapy/Body text
10/7/14openmedscience.com/68ga-somatostatin-analogue-pet-ct-in-neuroendocrine-tumors/Body text
10/25/14openmedscience.com/68ga-somatostatin-analogue-pet-ct-in-neuroendocrine-tumors/Body text
10/29/14openmedscience.com/68ga-somatostatin-analogue-pet-ct-in-neuroendocrine-tumors/Body text
10/30/14openmedscience.com/68ga-somatostatin-analogue-pet-ct-in-neuroendocrine-tumors/Body text
7/19/22openmedscience.com/68ga-somatostatin-analogue-pet-ct-in-neuroendocrine-tumors/Body text
7/19/22openmedscience.com/actinium-225-dota-ys5-a-novel-cd46-targeted-radiopharmaceutical-for-prostate-cancer-therapy/Body text
4/23/24openmedscience.com/.../medical-radiotherapeutics-scaled-e1705170545963.jpgLast modified header
6/19/20openmedscience.com/.../brain-imaging-e1592585931196.pngLast modified header
3/31/23openmedscience.com/.../F4_2015-0501-016.pngLast modified header
4/12/18openmedscience.com/.../F3_2015-0501-016.pngLast modified header
4/12/18openmedscience.com/.../F1_2015-0501-016.pngLast modified header
3/31/23openmedscience.com/.../F2_2015-0501-016-e1589878430163.pngLast modified header
3/31/23openmedscience.com/.../downloadpdf.pngLast modified header
3/31/23openmedscience.com/.../atheroma-e1589875842740.jpegLast modified header
8/26/21openmedscience.com/.../IMAGE-X1-scaled.jpgLast modified header

Twitteri

Help

This website does not appear to be associated with a Twitter account.

  • There was a problem checking the Twitter accounts associated with this website.

Popularityi

Help

  • Sorry, it was not possible to determine the popularity for this website.

Source: Ahrefs

Domain agei

Help

  • Sorry, we cannot check the domain age of .com websites.

Fast, branded website audits

Insites creates professional website reports that can be shared with your clients.

How does Insites compare?

Tests 17 fixed tests 50+ testsCovers SEO, SEM, Google My Business, reviews, social media and much more
Add your brandingNoYes
Export & shareNoPDF & link
Lead generationNoEmbed on your site
Competitor auditsNoYes
Test as a batchNoYes
Integrations + APINoYes
Multi-lingualNo20+ languages
Try it free